文献速递精神分裂症与精神病性障碍儿童青少年精神

布瑞哌唑治疗青少年精神分裂症的有效性与安全性:一项多国、随机、双盲、安慰剂对照、带活性参照的3期试验

Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference.
PubMed 文献 · Lancet Psychiatry · 2025-04-07

这项多国随机双盲安慰剂对照3期试验纳入316例13-17岁精神分裂症青少年,比较布瑞哌唑2-4 mg/日、安慰剂与阿立哌唑10-20 mg/日的短期疗效与安全性。第6周PANSS总分较基线变化:布瑞哌唑组-22.8,安慰剂组-17.4,最小二乘均值差-5.33(95%CI -9.55至-1.10;p=0.014)。布瑞哌唑安全性特征与成人试验一致。

要点

  • 布瑞哌唑2-4 mg/日组第6周PANSS总分较基线降低22.8,安慰剂组降低17.4,组间差异有统计学意义。
  • 布瑞哌唑组治疗中出现的不良事件报告44/110例(40%),安慰剂组42/104例(40%),阿立哌唑组53/102例(52%)。
  • 布瑞哌唑组严重治疗中出现的不良事件1/110例(1%),安慰剂组3/104例(3%),阿立哌唑组1/102例(1%),无死亡报告。

核心结论

  • 在青少年精神分裂症患者中,布瑞哌唑2-4 mg/日治疗6周与安慰剂相比症状严重程度降低更多。
  • 布瑞哌唑在青少年中的安全性特征与成人患者试验一致。
  • 这些结果补充了布瑞哌唑用于青少年精神分裂症的证据,可能有助于临床实践中的治疗选择。

研究设计与样本

  • 多国、随机、双盲、平行组、安慰剂对照、带活性参照的3期试验,在十个国家的62个门诊中心进行。
  • 纳入年龄13-17岁、主要DSM-5诊断为精神分裂症、筛选期和基线PANSS总分≥80的患者。
  • 患者按1:1:1随机分配至口服布瑞哌唑2-4 mg/日、安慰剂或阿立哌唑10-20 mg/日(活性参照)。
  • 主要疗效终点为基线至第6周PANSS总分变化,分析随机分配且至少接受一剂研究药物并有基线和基线后PANSS评估的患者。
  • 安全性在随机分配且至少接受一剂研究药物的患者中评估;试验注册号NCT03198078。

主要发现

  • 2017年6月29日至2023年2月23日筛选376例患者,316例随机分配至布瑞哌唑组(n=110)、安慰剂组(n=104)或阿立哌唑组(n=102)。
  • 患者平均年龄15.3岁(SD 1.5);316例中女性166例(53%),男性150例(47%)。
  • 第6周PANSS总分最小二乘均值较基线变化:布瑞哌唑组-22.8(SE 1.5),安慰剂组-17.4(SE 1.6),最小二乘均值差-5.33(95%CI -9.55至-1.10;p=0.014)。
  • 第6周阿立哌唑组PANSS总分变化为-24.0(SE 1.6),与安慰剂组最小二乘均值差-6.53(95%CI -10.8至-2.21;pnominal=0.0032,未针对多重检验校正)。
  • 治疗中出现的不良事件:布瑞哌唑组44/110例(40%),安慰剂组42/104例(40%),阿立哌唑组53/102例(52%);布瑞哌唑组最常见(发生率≥5%)为头痛(n=7)和恶心(n=7),阿立哌唑组为嗜睡(n=11)、疲乏(n=8)和静坐不能(n=7)。

关键数值与推荐

  • 主要疗效终点为基线至第6周PANSS总分变化。
  • 布瑞哌唑组与安慰剂组第6周PANSS总分最小二乘均值差-5.33(95%CI -9.55至-1.10;p=0.014)。
  • 阿立哌唑组与安慰剂组第6周PANSS总分最小二乘均值差-6.53(95%CI -10.8至-2.21;pnominal=0.0032,未针对多重检验校正)。
  • 布瑞哌唑和安慰剂组治疗中出现的不良事件发生率分别为40%和40%,阿立哌唑组为52%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New treatment options are needed for adolescent schizophrenia, partly due to an unfavourable risk-benefit profile of current options. This trial aimed to evaluate the short-term efficacy and safety of brexpiprazole in adolescents with schizophrenia. METHODS: This multicountry, randomised, double-blind, parallel-arm, placebo-controlled, phase 3 trial with an active reference was done at 62 outpatient sites in ten countries. Eligible patients were aged 13-17 years with a primary DSM-5 diagnosis of schizophrenia and a Positive and Negative Syndrome Scale (PANSS) total score ≥80 at screening and baseline. Patients were randomly assigned (1:1:1) to oral brexpiprazole 2-4 mg/day, placebo, or aripiprazole 10-20 mg/day (active reference). Patients, investigators, and sponsor personnel were masked to treatment assignment. The primary efficacy endpoint was change from baseline to week 6 in PANSS total score (in randomly assigned patients who took at least one dose of study drug and had baseline and post-baseline PANSS evaluations). Safety was assessed in randomly assigned patients who took at least one dose of study drug. People with lived experience of schizophrenia were not involved in the research or writing process. The trial was registered with ClinicalTrials.gov, NCT03198078, and is complete. FINDINGS: Between June 29, 2017, and Feb 23, 2023, 376 patients were screened, and 316 patients were randomly assigned to brexpiprazole (n=110), placebo (n=104), or aripiprazole (n=102). The mean age of patients was 15·3 years (SD 1·5). 166 (53%) of 316 patients were female and 150 (47%) were male. Of 316 patients, seven (2%) were American Indian or Alaskan Native, two (1%) were Asian, 21 (7%) were Black or African American, 204 (65%) were White, and 81 (26%) were other, as reported using US Census Bureau classifications. Mean doses of brexpiprazole and aripiprazole at last visit were 3·0 mg (SD 0·9) and 13·9 mg (4·7), respectively. Least squares mean change from baseline to week 6 in PANSS total score was -22·8 (SE 1·5) with brexpiprazole and -17·4 (1·6) with placebo (least squares mean difference -5·33 [95% CI -9·55 to -1·10]; p=0·014). The corresponding PANSS total score change at week 6 with aripiprazole was -24·0 (SE 1·6; least squares mean difference versus placebo -6·53 [95% CI -10·8 to -2·21]; pnominal=0·0032, not adjusted for multiple testing). Treatment-emergent adverse events were reported in 44 (40%) of 110 patients in the brexpiprazole group, 42 (40%) of 104 in the placebo group, and 53 (52%) of 102 in the aripiprazole group. The most common (incidence ≥5%) treatment-emergent adverse events were headache (n=7) and nausea (n=7) with brexpiprazole and somnolence (n=11), fatigue (n=8), and akathisia (n=7) with aripiprazole. Serious treatment-emergent adverse events were reported by one (1%) of 110 patients in the brexpiprazole group, three (3%) of 104 in the placebo group, and one (1%) of 102 in the aripiprazole group. No deaths were reported. INTERPRETATION: In adolescents with schizophrenia, brexpiprazole 2-4 mg/day was associated with greater reduction in symptom severity than placebo over 6 weeks. The safety profile of brexpiprazole in adolescents was consistent with trials in adult patients. These results add to the body of evidence for brexpiprazole in adolescents with schizophrenia and might help to inform treatment selection in clinical practice. FUNDING: Otsuka Pharmaceutical Development & Commercialization and H Lundbeck.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Ward C, Pejović Milovančević M, Kohegyi E, et al. Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference. Lancet Psychiatry. 2025. PMID: 40209740. doi:10.1016/S2215-0366(25)00043-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。